Research summary
Research HubGHK-Cu (Copper Peptide)
Clinical — 10 studies
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine, widely studied for its role in tissue remodeling, wound healing, and cellular regeneration.
Being studied for
- Wound healing and skin regeneration
- Collagen and elastin synthesis
- Anti-inflammatory activity
- Angiogenesis and tissue remodeling
- Hair follicle and skin biology research
Published Research
Evidence profile
Predominantly in-vitro and preclinical; the controlled human trials identified reported no benefit over control
10 cited publications · 2 primary trials
Evidence gap: Two randomised controlled human trials of GHK-Cu as a discrete agent were identified — a 1992 venous ulcer trial and a 13-patient trial after laser resurfacing. Neither separated from its control on the objective endpoints. No controlled human trial in cosmetic skin ageing, and no systematic review or meta-analysis, was identified.
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Core evidence
The publications most central to understanding this compound.
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
Miller TR et al. · Archives of facial plastic surgery · 2006
Population: 13 patients who completed circumoral carbon dioxide laser skin resurfacing
Patients undergoing circumoral CO2 laser resurfacing were randomised to a post-treatment skin regimen with or without a copper tripeptide complex, with erythema quantified by computer software and by blinded evaluators, wrinkles and overall skin appearance assessed at 12 weeks, and patient-reported outcomes captured on a validated questionnaire.
- Route reported
- Topical skin care products applied to laser-resurfaced skin under the study protocol
- Schedule
- Post-procedure regimen applied as directed under the trial protocol
- Duration
- Assessment through 12 weeks after treatment under the study protocol
- Treatment arms
- Post-treatment skin care regimen containing GHK-Cu · Post-treatment skin care regimen without GHK-Cu
“Computer analysis and blinded evaluators found no statistically significant differences between groups for earlier resolution of erythema.”
Context: Only 13 patients completed the study, so it is very small and underpowered; the objective endpoints showed no between-group separation, the setting is post-procedure wound recovery rather than routine cosmetic use, and the only difference reported was on a subjective questionnaire.
A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
Bishop JB et al. · Journal of vascular surgery · 1992
Population: 86 evaluable adult patients with chronic venous stasis ulcers
A randomised, evaluator-blinded trial compared two topical wound-healing agents against an inert vehicle placebo in adults with venous stasis ulcers, with change in ulcer size as the measured endpoint. The authors reported the outcome for a 0.4% tripeptide copper complex cream alongside a silver sulfadiazine comparator and the placebo arm.
- Route reported
- Topical application to the ulcer under the trial protocol
- Duration
- Trial duration not stated in the abstract
- Treatment arms
- Silver sulfadiazine 1% cream · Tripeptide copper complex 0.4% cream · Inert vehicle placebo cream
“There was no difference between the latter two treatments.”
Context: The trial studied chronic venous leg ulcers, not cosmetic or ageing skin, and it reports a null comparison for the tripeptide copper arm relative to placebo; the abstract does not state the application schedule or treatment duration, and no cosmetic endpoints were measured.
Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+)
Siméon A et al. · The Journal of investigative dermatology · 2000
Population: Sprague-Dawley rats with implanted subcutaneous wound chambers, plus cultured rat dermal fibroblasts
Using a rat subcutaneous wound-chamber model with parallel rat dermal fibroblast cultures, the authors measured wound tissue dry weight and total protein, type I collagen and glycosaminoglycan content, electrophoretic glycosaminoglycan profiles, and decorin and biglycan mRNA over a 22-day time course in chambers injected with the tripeptide-copper complex versus controls.
- Route reported
- Direct injection into the implanted subcutaneous wound chamber under the study protocol
- Schedule
- Repeated injections under the study protocol
- Duration
- Chambers analysed at intervals through day 22 under the study protocol
- Treatment arms
- Wound chambers receiving repeated GHK-Cu injections of 2 mg per injection · Control wound chambers
“Glycyl-histidyl-lysine-Cu(2+) treatment increased the mRNA level of decorin and decreased those of biglycan.”
Context: A rodent implanted-chamber model with direct injection of a milligram-scale dose, which is not comparable to topical cosmetic application in humans; it measures biochemical and mRNA markers of matrix turnover, not any clinical or appearance endpoint.
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
Maquart FX et al. · FEBS letters · 1988
Population: Cultured fibroblasts; the abstract does not name the donor species and the record is indexed under Humans
This early laboratory study measured collagen synthesis in fibroblast cultures exposed to the tripeptide-copper complex across a range of concentrations, alongside cell number, and noted the presence of a GHK triplet in the alpha-2(I) chain of type I collagen as a proposed origin of the peptide.
- Route reported
- Added to the fibroblast culture medium in vitro
- Treatment arms
- Fibroblast cultures exposed to GHK-Cu across a concentration range of approximately 10(-12) to 10(-9) M · Untreated culture comparison
“The stimulation began between 10(-12) and 10(-11) M, maximized at 10(-9) M, and was independent of any change in cell number.”
Context: A cell-culture experiment only: no animal or human skin was studied, the concentrations tested are laboratory conditions rather than anything achieved by topical application, and the abstract does not state the fibroblast donor species.
Supporting evidence
Human skin penetration of a copper tripeptide in vitro as a function of skin layer
Hostynek JJ et al. · Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2011
Population: Excised human skin preparations: isolated stratum corneum, heat-separated epidermis and dermatomed skin
This laboratory study applied an aqueous copper tripeptide solution to three excised human skin preparations in flow-through diffusion cells and used inductively coupled plasma mass spectrometry to quantify copper in the receptor fluid and retained in tissue over 48 hours, deriving a permeability coefficient for dermatomed skin.
- Route reported
- Topical application to excised human skin in flow-through diffusion cells (1 cm2 exposure area)
- Schedule
- Single infinite-dose application under the study protocol
- Duration
- 48 hours, with receptor fluid collected at 4-hour intervals
- Treatment arms
- 0.68% aqueous copper tripeptide applied under infinite dose conditions
“The permeability coefficient of the compound through dermatomed skin was 2.43 ± 0.51 × 10(-4) cm/h; 136.2 ± 17.5 μg/cm(2) copper permeated 1 cm(2) of that tissue over 48 h, while 97 ± 6.6 μg/cm(2) were retained as depot.”
Context: Excised skin in diffusion cells under infinite-dose conditions is not living skin and has no circulation or metabolism; the assay tracks copper rather than the intact tripeptide, and the authors' framing is transdermal anti-inflammatory delivery, not cosmetic use.
Safety literature
Reports of adverse events and individual cases. A case report describes what happened to one person; it cannot establish cause, and it cannot establish how often anything occurs.
Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds
Li H et al. · Scientific reports · 2016
Population: Cultured human keratinocytes (cell-line based skin irritation model)
This comparative laboratory study treated cultured human keratinocytes with three copper compounds and measured cell viability by tetrazolium reduction, cytotoxicity by lactate dehydrogenase release, and expression of irritation-related biomarkers (including IL-1 alpha, IL-8, HSPA1A and FOSL1) by real-time PCR and protein quantification.
- Route reported
- Compounds added to keratinocyte culture medium in vitro
- Schedule
- 24-hour treatment under the study protocol
- Duration
- 24 hours, at test concentrations including 58 and 580 micromolar
- Treatment arms
- Copper peptide (GHK-Cu) · Copper chloride (CuCl2) · Copper acetate (Cu(OAc)2)
“GHK-Cu was not cytotoxic and did not induce any significant change in the expression levels of various skin irritation-related biomarkers.”
Context: A monolayer keratinocyte screening assay, not a human patch test or clinical safety study; it addresses local irritation signals only and says nothing about systemic safety, sensitisation, or repeated real-world use.
Additional indexed literature (4)
- Preclinical · Mechanistic studyGlycyl-L-histidyl-L-lysine-Cu2(+) (GHK-Cu) Attenuates CuSO(4) or LPS induced-inflammation in Zebrafish larvae model
Hu J et al. · European journal of pharmacology · 2026 · PMID 41997403
- Preclinical · Mechanistic studyExploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms
Mao S et al. · Frontiers in pharmacology · 2025 · PMID 40672369
- Preclinical · Mechanistic studyCopper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects
Greco V et al. · Bioconjugate chemistry · 2025 · PMID 40123442
- Preclinical · Mechanistic studyGlycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway
Deng M et al. · Journal of cachexia, sarcopenia and muscle · 2023 · PMID 36905132
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
GHK-Cu has been extensively studied in laboratory and cosmetic research contexts. It is not approved as a medicinal product for therapeutic use.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.